Dyne Therapeutics, Inc. Forecasted to Earn FY2025 Earnings of ($2.94) Per Share (NASDAQ:DYN)

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Chardan Capital issued their FY2025 earnings estimates for shares of Dyne Therapeutics in a research report issued on Monday, May 6th. Chardan Capital analyst K. Nakae expects that the company will post earnings per share of ($2.94) for the year. Chardan Capital currently has a “Buy” rating and a $31.00 price target on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.27) per share.

Other equities analysts have also issued research reports about the company. Piper Sandler lifted their price target on Dyne Therapeutics from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. Stifel Nicolaus increased their price target on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the company a “buy” rating in a report on Wednesday, March 6th. Oppenheimer restated an “outperform” rating and issued a $47.00 price objective on shares of Dyne Therapeutics in a report on Monday. HC Wainwright reiterated a “buy” rating and set a $36.00 target price on shares of Dyne Therapeutics in a research note on Friday, May 3rd. Finally, Morgan Stanley started coverage on Dyne Therapeutics in a research note on Tuesday, April 30th. They issued an “overweight” rating and a $40.00 price target for the company. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $37.75.

Dyne Therapeutics Trading Up 1.0 %

Shares of NASDAQ:DYN opened at $25.95 on Wednesday. Dyne Therapeutics has a 12-month low of $6.40 and a 12-month high of $30.27. The stock has a market capitalization of $2.27 billion, a price-to-earnings ratio of -6.54 and a beta of 1.00. The stock has a fifty day simple moving average of $26.47 and a two-hundred day simple moving average of $18.93.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Tuesday, March 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.17).

Insider Activity

In other Dyne Therapeutics news, insider Wildon Farwell sold 1,585 shares of the business’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $25.70, for a total transaction of $40,734.50. Following the completion of the sale, the insider now directly owns 151,590 shares in the company, valued at approximately $3,895,863. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other Dyne Therapeutics news, insider Wildon Farwell sold 1,585 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $25.70, for a total value of $40,734.50. Following the transaction, the insider now directly owns 151,590 shares in the company, valued at $3,895,863. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Susanna Gatti High sold 1,591 shares of the business’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $25.85, for a total transaction of $41,127.35. Following the sale, the chief operating officer now directly owns 186,291 shares of the company’s stock, valued at approximately $4,815,622.35. The disclosure for this sale can be found here. Insiders have sold 1,875,432 shares of company stock valued at $44,368,530 in the last ninety days. 20.77% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Wetzel Investment Advisors Inc. purchased a new stake in Dyne Therapeutics in the 1st quarter worth approximately $28,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Dyne Therapeutics by 355.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,099 shares of the company’s stock worth $94,000 after purchasing an additional 5,541 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Dyne Therapeutics by 58.5% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,379 shares of the company’s stock valued at $75,000 after purchasing an additional 3,092 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in shares of Dyne Therapeutics by 95.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 9,310 shares of the company’s stock valued at $83,000 after buying an additional 4,552 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in Dyne Therapeutics in the 4th quarter worth $172,000. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.